SANDKI 360° powered by MIXMOVE
17.1.2023 11:30:00 EET | Business Wire | Press release
Skandi Network is the first unified network for healthcare distribution throughout Europe for human & veterinary healthcare products.
The network offers healthcare temperature-controlled transport for parcels and 1 to 5 pallet(s) shipments throughout 25 countries. Skandi Network is composed of 7 members who are all leading healthcare carriers. The main challenge of the network is to operate cross border transport shipments that involve cross docking operations.
“Having end-to-end visibility is already a challenge with one carrier but operating multi-county and multi-carrier operations at the same time is even more challenging. As we are transporting temperature sensitive healthcare products, we must guarantee that the products are transported in alignment with the GDP regulation and that temperature is monitored and always guaranteed. It is also important that our customers can have access to that information in real time.” -Rudy Smets, CEO of Skandi Network.
For these reasons, Skandi Network teamed up with MIXMOVE to develop a unique collaborative platform - Skandi 360° - to consolidate all operational and analytical data flows for all shipments going through the network.
One view and one access to the best-in-class healthcare transport network in Europe
Skandi Network is about giving access to the best-in-class healthcare transport network in Europe, working with 7 domestic leading freight forwarders. Skandi 360° will provide a coordinated solution to the market and its different stakeholders, giving them real time access and control of the first pan-European healthcare transport network (having over 4,780 vehicles and 165 temperature-controlled depots).
Connecting to Skandi 360° will allow them to expand, and/or optimise, their own capacities in a consolidated approach.
CO2 emissions reduction
In addition, Skandi 360° will also give an opportunity to reduce the carbon footprint and the cost of ownership throughout the whole transport chain. This includes:
- Consolidation of flows,
- Optimisation of logistics networks via regional distribution centres,
- No additional passive packaging needed in the network,
- And a reduction of damages and product loss during transport thanks to temperature monitoring.
Digitalising Logistics with MIXMOVE
MIXMOVE can integrate a very large amount of information and data coming from different sources and IT systems (like TMS, telematic systems, WMS, ERP). The MIXMOVE technology turns vertical and independent data flows into a flexible and consolidated One view/One access to data, all the way up to parcel/shipment level.
MIXMOVE also makes it possible to combine transport network functionalities and collaborative platform functionalities. This enables the management of the transport network in a lean and efficient way, creating real added value for all users of Skandi Network.
MIXMOVE tailors its technology to suit specific constraints linked to the healthcare transport business, including the regulations around integrating quality management, real-time temperature follow-up (including corrective and preventive actions), and POD’s that include an end-to-end temperature curve.
“We have chosen MIXMOVE for their proven expertise in the global supply chain and their proven technology to manage complex transport network operations. They use an advanced cloud-based technology with API connectivity. The MIXMOVE solution offers a capability to connect different systems and different tools (TMS, WMS, telematic systems…) seamlessly to the platform. This is what we needed, first to allow all members to be connected, and second to allow all external stakeholders, such as logistic service providers, to plug themselves into the platform and use our network." – Rudy Smets, CEO of Skandi Network.
About Skandi Network
Skandi Network is the first unified network for healthcare distribution throughout Europe for human & veterinary pharmaceuticals, biomedicals, APIs, temperature sensitive medical devices, diagnostics and general life products that are temperature sensitive. The network provides 2/8°C, 15/25°C and 20°C (in passive packaging) transport services and covers 25 countries thanks to the alliance of 7 leading healthcare carriers : Arra Group (Poland), BHS Logistics (Denmark, Sweden, Norway, Finland, Estonia, Latvia, Lithuania), BL Turkey Biopharma Logistics (Turkey), Eurotranspharma (France, Belgium, the Netherlands, Luxemburg, Spain, Czech Republic, Slovakia and also Germany, Austria and Slovenia via its existing local partner), Movianto (England, Scotland, Wales, Northern Ireland), PHSE (Italy), Rangel Logistics Solutions (Portugal). The aim of Skandi Network is to have members covering 36 countries by 2025. In total, the network members have more than 4,000 employees, operating in more than 4,780 temperature-controlled vehicles, 10 strategic regional consolidation platforms, 165 temperature controlled depots and transporting 14,750,000 temperature controlled shipments per year.
For more information : https://www.skandi-network.com/
About MIXMOVE
MIXMOVE provides a cloud solution supporting logistics by connecting systems, increasing profitability and reducing CO2 emissions.
For more than 10 years, MIXMOVE provides shippers, carriers and logistics service providers, the best customer experience in getting logistics transparency, predictability and resilience.
The main capabilities of the solution are focused on visibility, control and execution of transport & logistics services. Additional capabilities include optimising warehouse operations (like advanced cross-docking), order flow and fulfilment optimisation, planning automatisation, dispatching and routing optimisation.
MIXMOVE mobile applications enable digitalisation and collaboration with drivers. Trusted by customers like 3M, Volkswagen TPS, DHL, DSV, and Gebrüder Weiss, MIXMOVE has a proven track record in delivering high ROI, facilitating collaboration and helping achieve sustainability by improving resource utilisation.
For more information about MIXMOVE: www.mixmove.io
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005252/en/
Contact information
Rudy SMETS
CEO
mail@skandi-network.com
Dorothée DOSSMANN
Head of Marketing
dorothee.dossmann@mixmove.io
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
